|
|
|
|
|
|
|
|
|
|
Olaparib
"After halting development of its PARP inhibitor olaparib nearly 2 years ago, AstraZeneca is reviving the drug and launching two phase III trials based on a retrospective analysis of phase II data that showed a marked effect in ovarian cancer patients with a BRCA mutation."
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.